Cochrane · systematic review · CD001939
Branched‐chain amino acids for people with hepatic encephalopathy
Gluud, LL, Dam, G, Les, I, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 1 · 20%High 1 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsBranched‐chain amino acids (BCAA) versus control for hepatic encephalopathy
Population: people with hepatic encephalopathy.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Clinically Branched‐chain amino acids (BCAA) vs control | RR 0.88 [0.69, 1.11] | 15 studies · 760 participants | Moderate |
Hepatic encephalopathy Psychometric and clinical assessments Branched‐chain amino acids (BCAA) vs control | RR 0.73 [0.61, 0.88] | 16 studies · 827 participants | High |
Nausea and diarrhoea Clinically Branched‐chain amino acids (BCAA) vs control | RR 3.39 [0.7, 16.46] | 5 studies · 945 participants | Low Downgraded: imprecision, indirectness, publication bias |
Albumin Laboratory assessment Branched‐chain amino acids (BCAA) vs control | no estimate extracted | 3 studies · 176 participants | Low Downgraded: imprecision, indirectness, publication bias |
Nitrogen balance Laboratory assessment Branched‐chain amino acids (BCAA) vs control | no estimate extracted | 3 studies · 108 participants | Low Downgraded: imprecision, indirectness, publication bias |